Corvus Pharmaceuticals, Inc. (CRVS) News
Filter CRVS News Items
CRVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRVS News Highlights
- For CRVS, its 30 day story count is now at 3.
- Over the past 4 days, the trend for CRVS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CUE, AL and MG are the most mentioned tickers in articles about CRVS.
Latest CRVS News From Around the Web
Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
What Makes Corvus (CRVS) a New Buy StockCorvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialFigure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population) that were measurable by CT scan or by mSWAT for patients with cutaneous involvement. Figure 2: Swimmer Plot of Eligible Patient Population (N=21 evaluable, blue) and Ineligible Patient Population (N=11 evaluable, gray). Tumor histologies are al |
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year. |
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year. |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript November 7, 2023 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.16. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call. At this time, […] |
Q3 2023 Corvus Pharmaceuticals Inc Earnings CallQ3 2023 Corvus Pharmaceuticals Inc Earnings Call |
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsProtocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment New data from soquelitinib Phase 1 T cell lymphoma trial accepted for presentation at the 65th ASH Annual Meeting and Exposition New publications highlight therapeutic potential of ITK inhibition in solid tumors and multiple autoimmune and allergic conditions Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, |
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionBURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL), at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 9-12, 2023. Details regarding the poster presentation, which w |
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesData demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases Soquelitinib’s unique mechanism of action inhibited the production of Th2 and Th17 cells, providing upstream attenuation of several validated cytokine targets such as IL-4, IL-5, IL-13, IL-17 BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceu |
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1- |